Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
05:25pm, Friday, 17'th Oct 2025
Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of th
Is Trump Going to Kill the GLP-1 Cash Cow?
11:05am, Friday, 17'th Oct 2025
GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but Pres
WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage
09:10am, Friday, 17'th Oct 2025
Provides a Differentiated Cost-Sharing Framework for GLP-1 Medications Paired With Clinical Oversight and Proven Behavior Change Support from WeightWatchers Clinic Provides a Differentiated Cost-Shari
Lilly's oral GLP-1 drug helps reduce blood sugar levels in late-stage trials
06:51am, Wednesday, 15'th Oct 2025
Eli Lilly said on Wednesday its oral drug, orforglipron, helped reduce blood sugar levels in two late-stage trials.
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with ins
Global Partners Announces Cash Distribution on Series B Preferred Units
08:30am, Tuesday, 14'th Oct 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declare
Global Partners: A Midstream Underdog Ready For The Next Energy Upcycle
06:47am, Tuesday, 14'th Oct 2025
Global Partners LP is a leading midstream and retail energy MLP with strong cash flows and a robust, vertically integrated business model. GLP's recent acquisitions and disciplined capital management
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing i
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
07:00am, Tuesday, 07'th Oct 2025
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the po
Novo Nordisk: Oral Wegovy Nears FDA Decision As GLP-1 Momentum Builds
06:14am, Tuesday, 07'th Oct 2025
Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill. NVO's first-half 2025 results showed robust growth, driven by obesity fran
Poolbeg Pharma CEO on POLB001 & GLP-1 trial plans - ICYMI
02:40am, Saturday, 04'th Oct 2025
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington talked with Proactive about the company's interim results and key clinical milestones. Skillington highlighted that Poolbeg ended June
Global Partners' Preferred Stock Has Become Less Attractive
11:59pm, Wednesday, 01'st Oct 2025
Global Partners preferred stock's 9.2% dividend remains safe, backed by strong business momentum and resilient cash flow. GLP operates 1,700 fueling stations, benefiting from economies of scale and a
Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang
05:14am, Wednesday, 01'st Oct 2025
Fractyl Health delivered best-case results from its REMAIN-1 trial, with Revita patients continuing weight loss after GLP-1 discontinuation while placebo significantly rebounded. GUTS is still ~$230 m
Why This Beaten-Down GLP-1 Stock Could Be a Steal
09:15am, Tuesday, 30'th Sep 2025
Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize o
Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and treatm
